Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance—HIV drug resistance in sub-Saharan Africa and the Asia-Pacific
نویسندگان
چکیده
Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance—HIV drug resistance in sub-Saharan Africa and the Asia-Pacific Raph L Hamers,1*y Rebecca Oyomopito,2,3y Cissy Kityo, Praphan Phanuphak, Margaret Siwale, Somnuek Sungkanuparph, Francesca Conradie, Nagalingeswaran Kumarasamy, Mariette E Botes, Thira Sirisanthana, Saade Abdallah, Patrick C K Li, Nicoletta Ngorima, Pacharee Kantipong, Akin Osibogun, Christopher K C Lee, Wendy S Stevens, Adeeba Kamarulzaman, Inge Derdelinckx, Yi-Ming Arthur Chen, Rob Schuurman, Michèle van Vugt, Tobias F Rinke de Wit on behalf of the PharmAccess African (PASER) and TREAT Asia (TASER) Studies to Evaluate Resistancez
منابع مشابه
The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa.
The past decade has witnessed an unparalleled expansion of access to antiretroviral treatment for people living with HIV/ AIDS in sub-Saharan Africa. This historic public health achievement has saved the lives and improved the well-being of millions of people. Concern has been raised about rising drug-resistant HIV in resource-limited countries as a potential threat to the worldwide control of ...
متن کاملEarly warning indicators for population-based monitoring of HIV drug resistance in 6 African countries.
Human immunodeficiency virus (HIV) RNA testing and HIV drug resistance (HIVDR) testing are not routinely available for therapeutic monitoring of patients receiving antiretroviral therapy (ART) in resource-limited settings. World Health Organization HIVDR early warning indicators (EWIs) assess ART site factors known to favor the emergence of HIVDR. HIV drug resistance EWI monitoring was performe...
متن کاملBuilding capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network.
The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR...
متن کاملEffect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
BACKGROUND The effect of pretreatment HIV-1 drug resistance on the response to first-line combination antiretroviral therapy (ART) in sub-Saharan Africa has not been assessed. We studied pretreatment drug resistance and virological, immunological, and drug-resistance treatment outcomes in a large prospective cohort. METHODS HIV-1 infected patients in the PharmAccess African Studies to Evaluat...
متن کاملTransmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007–2010) – TASER-S
BACKGROUND The availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-naïve, recently infected HIV-posit...
متن کامل